SLC5A2 and type 2 diabetes mellitus: Dapagliflozin is a selective inhibitor of SGLT2 that blocks the glucose reabsorption in the proximal tubule of the kidney, promotes glucosuria, and induces clinically significant changes in the glycemic parameters in T2DM patients [29].